Here are three highlights from the first quarter:
1. Data from Ironwood’s investigational gastric retentive bile acid sequestrant demonstrated improvements in relief of heartburn and other symptoms.
2. Ironwood reported continued activity with a Phase IIa clinical study evaluating the ability of guanylate cyclase-C agonist to provide diabetic gastroparesis symptom relief.
3. Dosing began in a Phase I clinical study of he first clinical compound in a broad library of sGC stimulators for the potential treatment of cardiovascular disease.
More articles on GI/endoscopy:
UMass Memorial Medical Group adds Dr. Kerri Gosselin — 3 quick facts
Tissue-engineered small intestine successful — Is a new short bowel syndrome treatment next? 3 things to know
Cahaba GBA to cover EndoGastric Solutions’ TIF procedure: 4 important takeaways
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.